.
GREENLEAF IN THE NEWS
01.21.09 The Grey Sheet
Former CDRH Director Daniel Schultz joins Greenleaf Health.
10.02.09 Dow Jones Newswires
"The issue of off-label promotion has always been a delicate one for FDA, and clearly there are advantages and benefits to allowing companies to disseminate scientific journal articles," said Patrick Ronan, a former FDA chief of staff and currently head of Greenleaf Health LLC, a consultant to health-care companies on regulatory matters. Click below for article.
Allergan Sees Suit Against Government As Unique To Company
07.01.09 FDLI.org
Click below for FDLI's home page where you will find a link to hear
Dr. von Eschenbach's speech given at the FDLI & FDA 52nd Annual Conference.
06.22.09 The Paper
“Transformation of Healthcare” will be the focus of a lecture presented by former Federal Food and Drug Administration Commissioner Andrew von Eschenbach at a program sponsored by The Friendship Center July 23rd. Click below for more information.
The Friendship Center Hosts Former FDA Commissioner
06.11.09 POLITICO.com
Under the pretext of improving public health, the Senate is currently debating a bill that would give the Food and Drug Administration broad regulatory control over the tobacco industry. Andrew von Eschenbach, the former head of the FDA and also the former director of the National Cancer Institute and a cancer survivor, opposes the bill. Click below for article.
Tobacco Legislation is Smoke, Mirrors
06.06.09 GAIBP Annual Conference
Dr. Andrew von Eschenbach delivers keynote address at Global Alliance of Indian Biomedical Professionals.
Surviving in the Tough Economy - Opportunities and Challenges
04.30.09 The Pink Sheet
Former FDA Commissioner Andrew von Eschenbach spoke with PharmAsia News about international regulatory collaboration and his vision for the future of the agency. Click below to login for article.
Dr. Andrew von Eschenbach: An Interview with PharmAsia News
04.27.09 Milken Institute Global Conference 2009
Dr. Andrew von Eschenbach moderates panel discussion on wellness in the workplace at Milken Institute Conference. Click below for complete video of panel discussion.
Wellness in the Workplace: Obesity and Other Bottom Line Issues
04.27.09 The Tan Sheet
Dr. Andrew von Eschenbach questions FDA reorganization. Click below to login for article.
04.01.09 The RPM Report
When Former Commissioner Andrew von Eschenbach first got to the agency, he said, "FDA was on the verge of catastrophic failure. The agency needed to be resuscitated and now it has to be transformed." Click below to login for article.
Why Wait? Investors can Expect a More Proactive, Aggressive FDA.
03.27.09
Dr. Andrew c. von Eschenbach to speak at FDLI & FDA Annual Conference, April 22, 2009. Click below for more details.
FDLI & FDA 52nd Annual Conference, April 22-23, 2009
03.20.09 Connecticut Post
"Once you get an idea like this on Capitol Hill, it creates winners and losers in power and dollars, and when that happens, it usually results in a stalemate," said Patrick Ronan, a former FDA staffer and founder of Greenleaf Health consultants. Click below for article.
Drug Industry Joins Backers of FDA Split
03.03.09 BioWorld Today
"Biotech’s future is dependent on the new reality in
health care of integrating the parts and pieces of product
discovery, development and delivery," said former FDA
Commissioner Andrew von Eschenbach, who recently
joined Greenleaf Health LLC as a senior adviser. Click below for article.
Health Care Needs to be Reformed and Transformed
03.02.09 Forbes.com
As a result of the Ketek controversy, the FDA division that handles antibiotics "is one of, if not the most, difficult, environments to work in at the agency right now," according to Patrick Ronan, a former FDA chief of staff who now consults for health care companies. Click below for article.
02.25.09 Former FDA Commissioner Andrew von Eschenbach, MD, Joins Greenleaf Health
Greenleaf Health LLC. today announced that Andrew C. von Eschenbach, MD, who recently stepped down as Commissioner of the Food and Drug Administration (FDA), has joined the firm as Senior Advisor.
Press Release
Former FDA Commissioner Andrew von Eschenbach Joins Greenleaf Health
Related Articles
Former US FDA Chief to Advise Drug Makers - Reuters
Von Eschenbach Maps Out Role In Health Reform - In Vivo Blog
12.22.08 The Pink Sheet
"When you look at everything the FDA has on its plate right now...it becomes understandable why we've seen review times change a little bit," said Patrick Ronan, a former FDA chief of staff who is the founder of the consulting firm Greenleaf Health, LLC. Click below for article.
FDA Communication on Missed Deadlines Can Help Avoid...
12.19.08 Associated Press
"Personally, I'm much more optimistic in what the FDA may look like a year or two from now in terms of the industry's ability to get products through," said Patrick Ronan, a former FDA chief of staff who now runs a food and drug consulting business. Click below for article.
FDA OKs More Drugs, Still Misses Deadlines
12.15.08 The Pink Sheet
Restoring credibility "starts with a strong leader; someone who can set and drive the agenda," Ronan said. "When you have a strong person at the top that is willing to take on challenges and lead the agency in the right direction, it breeds success." Click below for article.
FDA Team Mentality: Commish Search Should Avoid...
11.19.08 The Wall Street Journal
"The FDA is a global regulatory body and expanding their footprint outside the U.S. is the first step in becoming more active in the global market,” Patrick Ronan, a former chief of staff at the FDA, tells the Health Blog. Click below for article.
How Do You Say FDA in Mandarin?